Technology giant Siemens (NYSE:SI) won FDA clearance to begin distributing the Artis Q and Artis Q.zen angiography systems in the U.S. The technology includes a new X-ray tube with lower radiation levels and updated software for more precise imaging, according to Siemens.

The Artis line is designed as a minimally invasive therapy to treat diseases including coronary artery disease, stroke and cancer. According to the German conglomerate, improvements to the Artis imaging systems enhance visibility of small vessels up to 70%.

Siemens is touting the approval as part of its Agenda 2013, a 2-year plan to develop MRI and radiography systems and push these products across the pond, according to a press release.

During its fiscal 1st quarter, Siemens’ profits rose 38% to $670 million, a success the company attributed to its strong imaging and therapy systems business.